An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy
- 399 Downloads
An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10 days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p ≤ 0.01]; OR, 0.91; 95% CI, 0.028–0.294) and less attributable mortality (0% versus 7.1%; p = 0.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.
KeywordsVancomycin Clostridium Difficile Infection Rifaximin Fidaxomicin Oral Vancomycin
We would like to thanks Thomas O’Boyle for his help in the preparation of the manuscript.
The preliminary results of this paper were presented at 26th European Congress of Clinical Microbiology and Infectious Diseases that was held in Amsterdam on April 2016.
Compliance with ethical standards
This work was partially supported by Fondo de Investigaciones Sanitarias (FIS), Research Project number PI13/00687, Carlos III Health Institute. Co-funded by the European Regional Development Fund (FEDER) “A way of making Europe”.
Conflicts of interests
The authors declare no conflicts of interest.
This study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón.
- 2.Labbe AC, Poirier L, Maccannell D, Louie T, Savoie M, Beliveau C, Laverdiere M, Pepin J (2008) Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52(9):3180–3187. doi: 10.1128/AAC.00146-08
- 6.Marin M, Martin A, Alcolea A, Iglesias C, Alcala L, Pelaez T, Sanchez-Somolinos M, Bouza E (2014) [First case of autochthonous Clostridium difficile PCR ribotype 027 detected in Spain]. Enferm Infecc Microbiol Clin 32(6):355–358 [In Spanish]. doi: 10.1016/j.eimc.2013.07.004 CrossRefPubMedGoogle Scholar
- 8.Debast SB, Bauer MP, Kuijper EJ (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1–26. doi: 10.1111/1469-0691.12418
- 9.Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31(5):431–455. doi: 10.1086/651706
- 12.Alcala L, Sanchez-Cambronero L, Catalan MP, Sanchez-Somolinos M, Pelaez MT, Marin M, Bouza E (2008) Comparison of three commercial methods for rapid detection of Clostridium difficile toxins a and B from fecal specimens. J Clin Microbiol 46(11):3833–3835. doi: 10.1128/JCM.01060-08 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, Pons JL (2004) Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 42(12):5710–5714CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Bajaj JS, Ananthakrishnan AN, Hafeezullah M, Zadvornova Y, Dye A, McGinley EL, Saeian K, Heuman D, Sanyal AJ, Hoffmann RG (2010) Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 105(1):106–113. doi: 10.1038/ajg.2009.615 CrossRefPubMedGoogle Scholar
- 26.Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP (2014) Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 12(8):1390.e2–1397.e2. doi: 10.1016/j.cgh.2013.12.021 CrossRefGoogle Scholar
- 27.Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071–1081. doi: 10.1056/NEJMoa0907893 CrossRefPubMedGoogle Scholar
- 28.Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, Kemmer N (2013) Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. J Clin Gastroenterol 47(2):188–192. doi: 10.1097/MCG.0b013e318276be13 CrossRefPubMedGoogle Scholar
- 30.Patrick Basu P, Dinani A, Rayapudi K, Pacana T, Shah NJ, Hampole H, Krishnaswamy NV, Mohan V (2010) Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 3(4):221–225. doi: 10.1177/1756283X10372985 CrossRefPubMedPubMedCentralGoogle Scholar